vida: extract claims from 2026-04-13-kff-glp1-access-inversion-by-state-income

- Source: inbox/queue/2026-04-13-kff-glp1-access-inversion-by-state-income.md
- Domain: health
- Claims: 1, Entities: 0
- Enrichments: 0
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/glp1-access-follows-systematic-inversion-highest-burden-states-have-lowest-coverage-and-highest-income-relative-cost.md

@@ -0,0 +1,17 @@
+---
+type: claim
+domain: health
+description: The healthcare system systematically denies access to the populations with the highest disease burden through the combination of state Medicaid policy and income distribution
+confidence: likely
+source: KFF + Health Management Academy, 2025-2026 Medicaid coverage and spending analysis
+created: 2026-04-13
+title: GLP-1 access follows systematic inversion where states with highest obesity prevalence have both lowest Medicaid coverage rates and highest income-relative out-of-pocket costs
+agent: vida
+scope: structural
+sourcer: KFF + Health Management Academy
+related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]", "[[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]]"]
+---
+
+# GLP-1 access follows systematic inversion where states with highest obesity prevalence have both lowest Medicaid coverage rates and highest income-relative out-of-pocket costs
+
+States with the highest obesity rates (Mississippi, West Virginia, Louisiana at 40%+ prevalence) face a triple barrier: (1) only 13 state Medicaid programs cover GLP-1s for obesity as of January 2026 (down from 16 in 2025), and high-burden states are least likely to be among them; (2) these states have the lowest per-capita income; (3) the combination creates income-relative costs of 12-13% of median annual income to maintain continuous GLP-1 treatment in Mississippi/West Virginia/Louisiana tier versus below 8% in Massachusetts/Connecticut tier. Meanwhile, commercial insurance (43% of plans include weight-loss coverage) concentrates in higher-income populations, creating 8x higher GLP-1 utilization in commercial versus Medicaid on a cost-per-prescription basis. This is not an access gap (implying a pathway to close it) but an access inversion—the infrastructure systematically works against the populations who would benefit most. Survey data confirms the structural reality: 70% of Americans believe GLP-1s are accessible only to wealthy people, and only 15% think they're available to anyone who needs them. The majority could afford $100/month or less while standard maintenance pricing is ~$350/month even with manufacturer discounts.